M&A Deal Summary |
|
---|---|
Date | 2019-11-11 |
Target | Aspen Global - Japanese Operations |
Sector | Life Science |
Buyer(s) | Sandoz International |
Sellers(s) | Aspen Global |
Deal Type | Divestiture |
Deal Value | 6.5B ZAR |
SEARCH BY
Try For Free 7-Day Free Trial
Sandoz International GmbH is a developer, manufacturer and markets generic pharmaceutical products focused on biosimilars, injectables, inhalers and transdermal patches.
DEAL STATS | # |
---|---|
Overall | 3 of 5 |
Sector (Life Science) | 2 of 4 |
Type (Divestiture) | 2 of 4 |
Country (Japan) | 1 of 1 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 3 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-12-19 |
AmLactin
Maple Grove, Minnesota, United States AmLactin is a developer, manufacturer of skin care products including therapeutic moisturizers and conditioners. AmLactin is based in Maple Grove, Minnesota. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-02-11 |
GSK - Cephalosporin Antibiotics Business
Brentford, United Kingdom GSK's Cephalosporin Antibiotics Business is a provider of antibiotics used to treat a range of bacterial infections. |
Buy | $500M |
South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. Aspen has production capabilities for a wide variety of product types including tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 2 of 2 |
Country (Japan) | 1 of 1 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-02-28 |
OTC Products
Grand Bay, Mauritius OTC Products are primarily sold through the mass retail channel and include the Herron® range of analgesics, vitamins and supplements. This basket of products is expected to generate at least $20 million in annual revenue. |
Sell | $51M |